Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix for Incident Dementia Diagnosis in Older Adults in Finland
NCT07502560Phase 4Recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Primary completion
- Apr 2030
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Zoster vaccine recombinant in Dementia, Alzheimer's disease (AD), sponsored by GSK. Started Mar 2026; status: recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
DementiaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07502560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502560.